- Home
- RPRX vs ARCC Comparison
RPRX vs ARCC Comparison
Compare RPRX & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ARCC
- Stock Information
- Founded
- RPRX 1996
- ARCC 2004
- Country
- RPRX United States
- ARCC United States
- Employees
- RPRX N/A
- ARCC N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ARCC Finance/Investors Services
- Sector
- RPRX Health Care
- ARCC Finance
- Exchange
- RPRX Nasdaq
- ARCC Nasdaq
- Market Cap
- RPRX 13.9B
- ARCC 15.5B
- IPO Year
- RPRX 2020
- ARCC 2004
- Fundamental
- Price
- RPRX $35.59
- ARCC $23.21
- Analyst Decision
- RPRX Strong Buy
- ARCC Buy
- Analyst Count
- RPRX 3
- ARCC 9
- Target Price
- RPRX $48.33
- ARCC $22.44
- AVG Volume (30 Days)
- RPRX 3.5M
- ARCC 3.5M
- Earning Date
- RPRX 08-06-2025
- ARCC 07-29-2025
- Dividend Yield
- RPRX 2.48%
- ARCC 8.27%
- EPS Growth
- RPRX 37.60
- ARCC N/A
- EPS
- RPRX 2.45
- ARCC 2.04
- Revenue
- RPRX $2,263,845,000.00
- ARCC $3,021,000,000.00
- Revenue This Year
- RPRX $29.35
- ARCC $2.84
- Revenue Next Year
- RPRX $7.58
- ARCC $5.53
- P/E Ratio
- RPRX $14.47
- ARCC $11.40
- Revenue Growth
- RPRX 1.13
- ARCC 12.01
- 52 Week Low
- RPRX $24.05
- ARCC $18.26
- 52 Week High
- RPRX $36.89
- ARCC $23.84
- Technical
- Relative Strength Index (RSI)
- RPRX 52.61
- ARCC 74.20
- Support Level
- RPRX $35.24
- ARCC $22.62
- Resistance Level
- RPRX $36.89
- ARCC $22.91
- Average True Range (ATR)
- RPRX 0.62
- ARCC 0.25
- MACD
- RPRX -0.14
- ARCC 0.09
- Stochastic Oscillator
- RPRX 22.16
- ARCC 86.82
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.